Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Capital Leases: 2019-2023

Historic Capital Leases for Beam Therapeutics (BEAM) over the last 4 years, with Sep 2023 value amounting to $304,000.

  • Beam Therapeutics' Capital Leases fell 78.10% to $304,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $304,000, marking a year-over-year decrease of 78.10%. This contributed to the annual value of $1.2 million for FY2022, which is 61.62% down from last year.
  • Beam Therapeutics' Capital Leases amounted to $304,000 in Q3 2023, which was down 65.26% from $875,000 recorded in Q2 2023.
  • Over the past 5 years, Beam Therapeutics' Capital Leases peaked at $5.3 million during Q1 2020, and registered a low of $304,000 during Q3 2023.
  • For the 3-year period, Beam Therapeutics' Capital Leases averaged around $2.2 million, with its median value being $1.8 million (2022).
  • As far as peak fluctuations go, Beam Therapeutics' Capital Leases climbed by 20.02% in 2020, and later crashed by 78.10% in 2023.
  • Beam Therapeutics' Capital Leases (Quarterly) stood at $4.4 million in 2019, then rose by 20.02% to $5.3 million in 2020, then crashed by 43.20% to $3.0 million in 2021, then tumbled by 61.62% to $1.2 million in 2022, then slumped by 78.10% to $304,000 in 2023.
  • Its last three reported values are $304,000 in Q3 2023, $875,000 for Q2 2023, and $983,000 during Q1 2023.